University of Oklahoma Receives $2.9M NCI Grant for Opaganib Trials
The grant will fund Phase 1b/2 trials of RedHill’s opaganib after CAR T therapy in ultra-high-risk multiple myeloma. RedHill is expected to supply the drug.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.